Shots:

• The P-III (PROGRESS) trial evaluates Qulipta (60mg, qd, 30mg, bid) vs PBO in 778 patients with chronic migraine
• The trial met its 1EPs i.e., the therapy showed a reduction from baseline in mean monthly migraine @12wk., improvements in all 2EPs for both efficacy analysis populations, 50% reduction in mean monthly migraine days @12wk., 41.0%/42.7% of patients achieved 50% reduction vs 26.0% in mITT population, 40.1%/42.1% achieved 50% reduction vs 26.5% in the OTHE population
• The safety profile was consistent with safety findings observed in previous studies in an EM population. The company plans to submit an sNDA with the US FDA for expanded use of atogepant to prevent chronic migraine

Ref: AbbVie | Image: AbbVie